These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 25105490

  • 1. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba ADM, Akkina R.
    Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
    [Abstract] [Full Text] [Related]

  • 2. Models for predicting effective HIV chemoprevention in women.
    Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, Kashuba AD.
    J Acquir Immune Defic Syndr; 2015 Apr 01; 68(4):369-76. PubMed ID: 25501616
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
    Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W.
    J Infect Dis; 2015 Dec 15; 212(12):1988-95. PubMed ID: 26071566
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA, Srinivasan P, Smith TJ, Butkyavichene I, Lopez G, Brooks AA, Martin A, Dinh CT, Smith JM, Baum MM.
    Antimicrob Agents Chemother; 2014 Sep 15; 58(9):5125-35. PubMed ID: 24936594
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
    Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.
    PLoS One; 2013 Sep 15; 8(1):e55013. PubMed ID: 23383037
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ, Taylor S, Back DJ, Khoo SH.
    Antivir Ther; 2011 Sep 15; 16(8):1139-47. PubMed ID: 22155898
    [Abstract] [Full Text] [Related]

  • 13. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
    Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R.
    PLoS One; 2010 Dec 21; 5(12):e15257. PubMed ID: 21203568
    [Abstract] [Full Text] [Related]

  • 14. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
    Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV.
    J Virol; 2011 Aug 21; 85(15):7582-93. PubMed ID: 21593172
    [Abstract] [Full Text] [Related]

  • 15. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S, Kang G, Prathipati PK, Zhou Y, Fan W, Li Q, Destache CJ.
    J Control Release; 2019 Jan 28; 294():216-225. PubMed ID: 30576746
    [Abstract] [Full Text] [Related]

  • 16. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W.
    J Virol; 2012 Jan 28; 86(2):718-25. PubMed ID: 22072766
    [Abstract] [Full Text] [Related]

  • 17. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.
    Sci Transl Med; 2011 Dec 07; 3(112):112re4. PubMed ID: 22158861
    [Abstract] [Full Text] [Related]

  • 18. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.
    Antimicrob Agents Chemother; 2009 May 07; 53(5):1937-43. PubMed ID: 19273671
    [Abstract] [Full Text] [Related]

  • 19. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
    Gao Y, Katz DF.
    PLoS One; 2013 May 07; 8(9):e74404. PubMed ID: 24040241
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.